Integrin beta-4 Antibodies

Integrin beta-4 (ITGB4)

Integrin alpha-6/beta-4 is a receptor for laminin. Plays a critical structural role in the hemidesmosome of epithelial cells.

Is required for the regulation of keratinocyte polarity and motility. ITGA6:ITGB4 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling (PubMed:20682778).

Gene Information

Human
Gene Name:	ITGB4
Uniprot:	P16144
Entrez:	3691

Family

Belongs to:
integrin beta chain family

Alternative Names

CD104 antigen; CD104; GP150; Integrin beta 4; integrin beta-4 subunit; integrin beta-4; integrin, beta 4; ITGB4

Molecular Weight

Mass (kDA):
202.167 kDA

Genomic Context

Human
Location:	17q25.1
Sequence:	17; NC_000017.11 (75721339..75757819)

Tissue Specificity

Integrin alpha-6/beta-4 is predominantly expressed by epithelia. Isoform beta-4D is also expressed in colon and placenta. Isoform beta-4E is also expressed in epidermis, lung, duodenum, heart, spleen and stomach.

Subcellular Localizations

Cell membrane; Single-pass type I membrane protein. Cell membrane; Lipid-anchor. Cell junction, hemidesmosome. Colocalizes with DST at the leading edge of migrating keratinocytes.

Diseases

• Epidermolysis Bullosa
• Atresia
• Malignant Neoplasms
• Junctional Epidermolysis Bullosa
• Bulla
• Tissue Adhesions
• Epidermolysis Bullosa Junctionalis With Pyloric Atresia
• Neoplasms
• Neoplasm Metastasis
• Carcinoma
• Cell Invasion

• Malignant Neoplasm Of Breast
• Malignant Squamous Cell Neoplasm
• Skin Diseases, Genetic
• Dermatologic Disorders
• Malignant Paraganglionic Neoplasm
• Malignant Neoplasm Of Lung

Interacting Proteins

• ARRDC3
• ITGA6
• PLEC
• PTK2
• S1PR2

• S1PR3

Pathways

• Cell Adhesion
• Cell Proliferation
• Cell Migration
• Immune Response
• Translation
• Pathogenesis
• Cell Cycle
• Invasive Growth
• Cell Growth
• Angiogenesis
• Transport
• Cell Activation
• Neutrophil Extravasation

• Adaptive Immune Response
• Regulation Of Gene Expression
• Myelination
• Mesenchymal Cell Migration
• Inflammatory Response
• T Cell Proliferation
• Secretory Pathway

PTMs

• Disulfide bond
• Glycoprotein

• Lipoprotein
• Palmitate

• Phosphoprotein

Research Areas

• Adaptive Immunity
• Immunology
• Signal Transduction

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/ITGB4

Boster Bio - Best Uses Of The ITGB4 Marker

Boster Bio might be a good option for you. This article will explain the ITGB4 marker and how you can maximize its use. It also offers Boster Bio optimization tips. This article also explains how to make use of the ITGB4 marker. There is Boster Bio test that can suit you, whether you are a scientist or a customer.

Anti-Integrin beta 4/ITGB4 Marker

Boster Bio's Anti-Integrin beta4/ ITGB4 Marker is part of their Picoband (tm) catalog. This antibody has been tested in ELISA and IHC as well as WB. This antibody reacts with Rat, Mouse, and Human. It has been used to investigate the expression of ITGB4 in many human tumors.

In squamous cell carcinoma the expression of integrin a6b4 is associated with poor prognosis. This protein is also expressed in tumor cells of mice. Subcutaneous injections of this protein into nude mice cause tumor-initiating cells to develop. expression of conditional alleles of the b4 gene. These types of cells that initiate tumors can develop into well-differentiated tumors. In addition, the activity of the tumor-suppressor is dependent on the genetic background of cells.

It has been identified as the ligand that supports dynamic adhesion. Under stress from fluids the beta 6 alpha 4 positive cells bonded quickly to laminin. The attached cells began to roll as the flow rate increased. The adhesion is formed quickly and is easily repaired. The ligand responsible for facilitating dynamic adhesion is laminin fragment E8. Fibronectin in contrast, did not support dynamic adhesion.

In a study by Vidal and co. changes in the ITGB4 gene led to compound heterozygosity for this gene in an infant suffering from junctional epidermolysis bullosa. This genetic condition is associated with pyloric atresia. Vidal et. al. recently discovered that an infant suffering from this condition was born with an ITGB4 mutation. This was a compound heterozygosity.

These two proteins were identified to aid in the interaction between Integrin b4 and PVRL4. This association was found to depend on the presence of PVRL4. The fusion of these proteins is essential for anchorage-independent growth and adhesion. In mice, the growth rate of breast cancer was significantly reduced by the depletion of PVRL4.

Application

The ITGB4 marker is a protein highly expressed in certain cancer types. The TIMMER2 test examines the ITGB4 protein. The level of phosphorylation of the ITGB4 protein differs based on the type of cancer. This marker has been used in assessing the prognosis of cancer. However more research is required before it can be widely utilized. Here are some essential facts about ITGB4 and cancer prognosis.

In mesenchymal cells like MDA-MB-231 and SUM159 The ITGB4 protein is found on the cell's surface. FACS analysis revealed that cells with ITGB4 were more likely to be tumorigenic than those lacking the protein. They also showed higher differentiation in the mesenchymal lineage than their isogenic counterparts. They also had a higher tumorigenic potential than isogenic samples.

This marker can identify tumor cells that contain the transmembrane integrin B4 protein. It is involved in tumorigenesis and development of many types of cancers, however it has not been extensively studied in the context of pan-cancer. Our study draws on data from the Cancer Genome Atlas, Gene Expression Omnibus, and shows the first evidence of an oncogenic effect for ITGB4. If used correctly when it is used correctly, the ITGB4 marker can help in identifying tumors early in their development.

Recent research has demonstrated that the ITGB4 marker is a valuable biomarker for identifying TNBC breast cancer cells in CSC-enriched populations. This new marker will be useful in determining if the cells have the EMT program. This marker can differentiate between different subpopulations. There is a need for additional markers that enable more precise analysis of the CSC population.

A total of 82 patients with HCC were tested for ITGB4 by using immunohistochemical staining and real-time QPCR. The results of qRT-PCR showed that tumors expressing ITGB4 have significantly higher levels of the protein than the adjacent non-tumor tissue. The high levels of ITGB4 found in tumors were also observed to be more protracted and stage-prone than non-tumor tissues.

In addition to its function in the progression of tumors, ITGB4 also regulates the activity of a range of other molecules, including Nanog, Sox2 and Yba1. It also aids in HCC growth, regulates EMT and is responsible for controlling metastasis. ITGB4 interacts with numerous cells in the body, including Nanog and Sox2.

It is important to know the genes that regulate the ITGB4 marker to conduct cancer research. RNAi therapy triggers nuclear transfer of ITGB4, while SEC-mediated ITGB4 expression doesn't have any effect on normal cells. ANXA7 is also known to regulate the ITGB4 gene. This means that SEC-activated ITGB4 is vital to the survival of tumor cells.